Objective The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic. The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan-based technology of Archimedes Development Ltd.. Chitosan has already been tested with several nasally delivered antigens pre-clinically and clinically with excellent results. The most effective way of controlling a pandemic flu would be via the nasal route as this route is advantaged to generate both systemic and mucosal antibodies; the latter allowing virus control at its point of entry. In comparison the currently used injection route cannot achieve the mucosal response. Intranasal vaccination has further advantages: avoids the need for injection and safe disposal of syringes, eliminate the risk of HIV transmission through re-use or accidental contact with body fluids, have greater public compliance and well-suited to rapid mass global vaccination programmes. The scientific objectives of the project are: induce both systemic and mucosal immunity, evaluation of efficacy and toxicity in preclinical studies, evaluation of efficacy and safety profile in humans, provide a substantial level of cross-immunity against a drifted strains of H5 or H7, effective at low dose to meet the global demands from limited vaccine stockpiles, thermal stability so as to avoid refrigeration for storage and transportation and user friendly vaccine applicator. The consortium members have extensive experience in their specialist fields which would enable the success of this project. ChiSys® would be an excellent candidate for developing an intranasal pandemic influenza vaccine to provide a quantum leap in successfully combating pandemic influenza globally. Fields of science natural sciencesbiological sciencesmicrobiologyvirologymedical and health scienceshealth sciencespublic healthepidemiologypandemicsmedical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenzamedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Keywords chitosan influenza nasal pandemic vaccine Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH-2007-2.3.3-1 - Development of broadly protective influenza vaccine candidates Call for proposal FP7-HEALTH-2007-A See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator ARCHIMEDES DEVELOPMENT LIMITED EU contribution € 977 621,40 Address Albert Einstein Centre Nottingham Science and Technology Park NG7 2TN Nottingham United Kingdom See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Anthony Rhodes (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (7) Sort alphabetically Sort by EU Contribution Expand all Collapse all UNIVERSITY OF LEICESTER United Kingdom EU contribution € 97 812,00 Address UNIVERSITY ROAD LE1 7RH Leicester See on map Region East Midlands (England) Leicestershire, Rutland and Northamptonshire Leicester Activity type Higher or Secondary Education Establishments Administrative Contact Marie Singer (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data HEALTH PROTECTION AGENCY HPA United Kingdom EU contribution € 80 106,00 Address BUCKINGHAM PALACE ROAD 151 SW1W 9SZ London See on map Activity type Research Organisations Administrative Contact Amanda King (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data RETROSCREEN VIROLOGY LTD United Kingdom EU contribution € 1 017 929,60 Address NEW ROAD QUEEN MARY BIOENTERPRISE INNOVATION CENTRE 42 E1 2AX LONDON See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact John Oxford (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN Ireland EU contribution € 494 016,00 Address COLLEGE GREEN TRINITY COLLEGE D02 CX56 DUBLIN 2 See on map Region Ireland Eastern and Midland Dublin Activity type Higher or Secondary Education Establishments Administrative Contact Deirdre Savage (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITETET I BERGEN Norway EU contribution € 504 167,00 Address MUSEPLASSEN 1 5020 Bergen See on map Region Norge Vestlandet Vestland Activity type Higher or Secondary Education Establishments Administrative Contact Inger Gjesdahl (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSITA DEGLI STUDI DI SIENA Italy EU contribution € 245 250,00 Address VIA BANCHI DI SOTTO 55 53100 Siena See on map Region Centro (IT) Toscana Siena Activity type Higher or Secondary Education Establishments Administrative Contact Silvano Focardi (Prof.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data EVICOM LTD United Kingdom EU contribution € 156 746,00 Address Lyndhurst Road, Ascentia House SL5 9ED ASCOT See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Alastair Knight (Dr.) Links Contact the organisation Opens in new window Total cost No data
